Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in India
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
Novavax and SK bioscience announed expanded manufacturing agreement
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
Novavax announced initiation of PREVENT-19 COVID-19 vaccine phase 3 trial booster study
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
Llama antibodies could help fight SARS-CoV-2 variants
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the Philippines
On Nov. 17, 2021, Novavax and and Serum Institute of India announced that the Philippine Food and Drug…
Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch system
On Nov. 17, 2021, Zosano Pharma announced that the Philippine Food and Drug Administration had granted emergency use…
Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373
On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…
Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies
On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…
COVID-19 | Nanotechnology | Vaccine | WHO
Novavax filed COVID-19 vaccine for Emergency Use listing with World Health Organization
On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…
Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia
On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…
Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…
The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis C
On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…
Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…
The Priestley Medal was awarded to Paul Alivisatos
On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine
On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant…
NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxfordﾒs Nuffield Department of Medicine published their evaluation of…
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…